We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail
Read MoreHide Full Article
Penumbra (PEN - Free Report) is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movement and rising expenses are major dampeners for Penumbra. The stock presently carries a Zacks Rank #3 (Hold).
Factors Driving PEN Shares
Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States, as well as its Computer-Assisted Vacuum Thrombectomy (CAVT) line of products. In this region, the company is benefiting from sales of new products and further market penetration of existing products. In the fourth quarter of 2024, the company delivered 27.3% year-over-year growth in thrombectomy in the United States, driven by continued adoption and further market penetration of the current CAVT Portfolio, Lightning Flash 2.0 and Lightning Bolt 7. The U.S. VTE franchise delivered revenue growth of 41% year over year.
Penumbra derives a significant portion of its revenues internationally (24.5% in 2024). The company expects to materially increase both revenues and profitability in its international business in the next few years. During this period, the company expects to bring its franchise products, such as RED catheters and CAT RX, together with all its most advanced products, Lightning Flash, Lightning Bolt 7 and Thunderbolt, to Penumbra global teams.
Penumbra is still in the early stages of its journey to bring the company’s proprietary thrombectomy technologies to patients in the United States and around internationally. In terms of product launch, the Element Vascular Access System was launched in January 2025. This laser-cut hypotube sheath is designed for venous thromboembolism treatments and is compatible with the Lightning Flash 2.0 thrombectomy system.
Penumbra also launched its Lightning Bolt 12 and Lightning Bolt 6x with TraX in 2025. These additions to Penumbra's CAVT platform aim to enhance arterial and venous thrombus management. In terms of pipeline, the company plans to strongly focus on Flash and Bolt innovations.
Over the past three months, shares of PEN have gained 18.5% compared with the industry’s 4.8% growth. The company’s consistent efforts to expand its high-growth thrombectomy business and its array of new product launches are expected to help the stock continue with its uptrend in the coming days.
Concerns Remain for Penumbra
A significant portion of Penumbra’s sales and costs are exposed to changes in foreign exchange rates. In 2024, approximately 29% of the company's consolidated revenues came from the non-U.S. markets. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income.
Like other industry players, Penumbra’s business is currently impacted by worldwide geopolitical complications, which have a widespread impact on global supply chains and labor markets. These have resulted in cost escalation and raw material supply constraints, as well as an increase in employee turnover rates in certain jurisdictions. All these factors are putting significant pressure on Penumbra’s profitability. In the fourth quarter of 2024, Penumbra incurred a 7.3% rise in the cost of revenues. Selling, general and administrative expenses rose 13.8% year over year.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health has an estimated fiscal 2025 earnings growth rate of 62.1% compared with the industry’s 15.4%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 27.06%. Its shares have surged 68.2% compared with the industry’s 12.5% growth in the past year.
Boston Scientific, presently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.7% compared with the industry’s 1.4%. Shares of the company have rallied 56.9% compared with the industry’s 12.5% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.3%.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 10.7% compared with the industry’s 9.4%. Shares of the company have rallied 15.9% against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail
Penumbra (PEN - Free Report) is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movement and rising expenses are major dampeners for Penumbra. The stock presently carries a Zacks Rank #3 (Hold).
Factors Driving PEN Shares
Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States, as well as its Computer-Assisted Vacuum Thrombectomy (CAVT) line of products. In this region, the company is benefiting from sales of new products and further market penetration of existing products. In the fourth quarter of 2024, the company delivered 27.3% year-over-year growth in thrombectomy in the United States, driven by continued adoption and further market penetration of the current CAVT Portfolio, Lightning Flash 2.0 and Lightning Bolt 7. The U.S. VTE franchise delivered revenue growth of 41% year over year.
Penumbra derives a significant portion of its revenues internationally (24.5% in 2024). The company expects to materially increase both revenues and profitability in its international business in the next few years. During this period, the company expects to bring its franchise products, such as RED catheters and CAT RX, together with all its most advanced products, Lightning Flash, Lightning Bolt 7 and Thunderbolt, to Penumbra global teams.
Penumbra is still in the early stages of its journey to bring the company’s proprietary thrombectomy technologies to patients in the United States and around internationally. In terms of product launch, the Element Vascular Access System was launched in January 2025. This laser-cut hypotube sheath is designed for venous thromboembolism treatments and is compatible with the Lightning Flash 2.0 thrombectomy system.
Penumbra also launched its Lightning Bolt 12 and Lightning Bolt 6x with TraX in 2025. These additions to Penumbra's CAVT platform aim to enhance arterial and venous thrombus management. In terms of pipeline, the company plans to strongly focus on Flash and Bolt innovations.
Penumbra, Inc. Price
Penumbra, Inc. price | Penumbra, Inc. Quote
Over the past three months, shares of PEN have gained 18.5% compared with the industry’s 4.8% growth. The company’s consistent efforts to expand its high-growth thrombectomy business and its array of new product launches are expected to help the stock continue with its uptrend in the coming days.
Concerns Remain for Penumbra
A significant portion of Penumbra’s sales and costs are exposed to changes in foreign exchange rates. In 2024, approximately 29% of the company's consolidated revenues came from the non-U.S. markets. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income.
Like other industry players, Penumbra’s business is currently impacted by worldwide geopolitical complications, which have a widespread impact on global supply chains and labor markets. These have resulted in cost escalation and raw material supply constraints, as well as an increase in employee turnover rates in certain jurisdictions. All these factors are putting significant pressure on Penumbra’s profitability. In the fourth quarter of 2024, Penumbra incurred a 7.3% rise in the cost of revenues. Selling, general and administrative expenses rose 13.8% year over year.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health has an estimated fiscal 2025 earnings growth rate of 62.1% compared with the industry’s 15.4%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 27.06%. Its shares have surged 68.2% compared with the industry’s 12.5% growth in the past year.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Boston Scientific, presently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.7% compared with the industry’s 1.4%. Shares of the company have rallied 56.9% compared with the industry’s 12.5% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.3%.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 10.7% compared with the industry’s 9.4%. Shares of the company have rallied 15.9% against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.6%.